Robert Lanza insider trades: Ocata Therapeutics (OCAT) stock sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Robert reports to the SEC
Open-market buys and sales
19 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Nov 10, 2015 | OCAT | ↓ Sell10b5-1 | 35,000 | $8.31 | $291K | Direct | Nov 10, 2015 (0d) |
| Sep 10, 2014 | ACTCD | ↓ Sell10b5-1 | 8,930 | $12.53 | $112K | Direct | Sep 11, 2014 (1d) |
| Sep 8, 2014 | ACTCD | ↓ Sell10b5-1 | 15,000 | $10.05 | $151K | Direct | Sep 9, 2014 (1d) |
| Sep 3, 2014 | ACTCD | ↓ Sell10b5-1 | 25,000 | $8.65 | $216K | Direct | Sep 4, 2014 (1d) |
| Jul 7, 2014 | ACTC | ↓ Sell10b5-1 | 1,500,000 | $0.08 | $120K | Direct | Jul 7, 2014 (0d) |
| Dec 14, 2012 | ACTC | ↓ Sell | 1,338,490 | $0.06 | $79K | Direct | Dec 18, 2012 (4d) |
| Jul 31, 2012 | ACTC | ↓ Sell | 2,000,000 | $0.08 | $161K | Direct | Aug 1, 2012 (1d) |
| Jan 24, 2012 | ACTC | ↓ Sell | 7,658,300 | $0.19 | $1.5M | Direct | Jan 25, 2012 (1d) |
| Sep 29, 2011 | ACTC | ↓ Sell | 726,305 | $0.15 | $111K | Direct | Sep 30, 2011 (1d) |
| Dec 7, 2010 | ACTC | ↓ Sell | 2,000,000 | $0.14 | $278K | Direct | Dec 8, 2010 (1d) |
| Nov 30, 2010 | ACTC | ↓ Sell | 4,800,000 | $0.10 | $466K | Direct | Dec 1, 2010 (1d) |
| Nov 23, 2010 | ACTC | ↓ Sell | 1,455,900 | $0.07 | $106K | Direct | Nov 24, 2010 (1d) |
| Nov 23, 2010 | ACTC | ↓ Sell | 5,100 | $0.08 | $393 | Direct | Nov 24, 2010 (1d) |
| Sep 20, 2010 | ACTC | ↓ Sell | 600,000 | $0.07 | $41K | Direct | Sep 22, 2010 (2d) |
| Aug 20, 2010 | ACTC | ↓ Sell | 600,000 | $0.08 | $45K | Direct | Aug 23, 2010 (3d) |
| Jul 21, 2010 | ACTC | ↓ Sell | 600,000 | $0.07 | $42K | Direct | Jul 22, 2010 (1d) |
| Jun 21, 2010 | ACTC | ↓ Sell | 600,000 | $0.10 | $58K | Direct | Jun 23, 2010 (2d) |
| May 20, 2010 | ACTC | ↓ Sell | 600,000 | $0.07 | $39K | Direct | May 21, 2010 (1d) |
| Apr 20, 2010 | OTCBB:ACTC | ↓ Sell | 439,023 | $0.09 | $40K | Direct | Apr 23, 2010 (3d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
About Robert Lanza's insider trades
Robert Lanza is Chief Scientific Officer at Ocata Therapeutics (OCAT). Since Apr 20, 2010, Robert has reported no open-market purchases and 19 sales worth $3.8M on SEC Form 4. There have been no open-market trades in the last 12 months.
5 sales (23% of the value sold) were made under a Rule 10b5-1 trading plan, which is set up months in advance and runs on a schedule, so they say little about how the insider sees the stock today.
Their filings also include grants and awards (11 filings), other transactions (1 filing), shares returned to the company (1 filing), option exercises (1 filing). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every OCAT insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.